New way to fight sepsis: Rev up patients' immune systems

March 8, 2018, Washington University School of Medicine
Richard Hotchkiss, MD, a professor of anesthesiology (left), and Jane Blood (right), a nurse manager in the Department of Anesthesiology's Division of Clinical and Translational Research, talk with Greg Porter, 34, of Nashville, Ill., who has recovered from sepsis. Porter participated in a clinical trial at Washington University School of Medicine in St. Louis. The researchers found that a drug that revs up the immune system holds promise in treating sepsis. Credit: Huy Mach

While many people have never heard of sepsis, it causes about 250,000 deaths annually in the United States. The condition develops when an infection triggers an overwhelming immune response, ultimately wreaking havoc on the immune system. Standard treatment involves high doses of antibiotics that fight the infection, but they often don't work well and fail to boost the body's immune defenses.

Now, a small clinical trial led by researchers at Washington University School of Medicine in St. Louis shows that a drug that revs up the holds promise. The approach goes against the grain of earlier strategies that have relied on antibiotics and inflammatory medications to tamp down the immune system.

Their findings are published March 8 in the journal JCI Insight.

"Mortality rates from sepsis have remained essentially the same over the last 50 years," said senior investigator Richard S. Hotchkiss, MD, a professor of anesthesiology, of medicine and of surgery. "Hundreds of drugs have been tried and have failed. It may sound counterintuitive when inflammation is such a problem early in sepsis, but our approach is to stimulate certain immune cells to help the patient's system take control of the infection."

The trial involved 27 sepsis patients, ages 33 to 82, who were treated at Barnes-Jewish Hospital in St. Louis, Vanderbilt University Medical Center in Nashville or two medical centers in France—Dupuytren University Hospital in Limoges and Edouard Herriot Hospital in Lyon. Although the study was too small to see a statistical benefit in mortality, the researchers noted an improved immune response in patients who were given a drug to beef up their immunity.

The patients were treated with a drug made of interleukin-7 (IL-7), which enhances the proliferation and survival of two types of immune cells: CD4 and CD8. These cells are important because they recruit other immune cells to fight severe infections that can lead to organ failure and death.

Sepsis and its more severe form called septic shock are among the deadliest problems facing patients in intensive care units. The conditions occur when the body has an extreme response to infection, and traditional treatments often aim to limit inflammation by tamping down a septic patient's immune system. But in a new, multi-center trial, an international team of researchers has shown that strengthening part of the immune system may be more effective in the long run. jim dryden has the story... Credit: Washington University BioMed Radio

"Patients who develop the most serious form of sepsis, called septic shock, often have very low counts of these key immune cells," said co-investigator Edward R. Sherwood, MD, PhD, a professor of anesthesiology at Vanderbilt. "We believe that could play a role in the development and course of sepsis because without those cells, patients aren't able to clear as much harmful bacteria."

The patients in the trial, who were hospitalized and severely ill with septic shock, were randomly assigned to one of two therapies. Seventeen patients received the IL-7 drug, and 10 received a standard treatment. Those who received the drug experienced a threefold to fourfold increase in CD4 and CD8 counts.

"Even though the study was small, we were encouraged that IL-7 helped restore key cells in the immune systems of these patients," said Andrew H. Walton, a staff scientist in the Hotchkiss lab and co-author of the study. "Overall, that should help improve patient survival."

The researchers showed that IL-7 boosts adaptive immunity, in which CD4 and CD8 T cells help recruit other —called macrophages, monocytes, neutrophils and dendritic cells—to kill bacteria that cause infections. Traditional approaches to sepsis therapy do not address the critical problem of patients' severely compromised immune systems. Without restoring , Hotchkiss said, many patients develop lingering infections and are helpless to fight any new infections.

"We know that 40 percent of patients die in the 30- to 90-day period after the initial septic ," Hotchkiss said. "Their bodies can't fight secondary infections, such as the blood infections and staph infections that can develop later on because their immune systems are shot. By strengthening adaptive immunity with IL-7 and increasing the numbers of CD4 and CD8 available to help fight infections, we think this approach can make a big difference."

Hotchkiss credits recent approaches to cancer treatment as evidence that this strategy for sepsis therapy may be a game changer for many patients. Several cancer researchers have begun using IL-7 to rev up a patient's own immune system to fight cancer. In addition, under compassionate-use guidelines, IL-7 has been given to some critically ill patients with serious viral infections and has successfully restored their CD4 and CD8 counts while improving survival.

As a next step, Hotchkiss and Sherwood are planning a larger trial to determine whether the same holds true for patients. They estimate a study involving 300 to 400 should have the statistical strength to determine whether IL-7 can improve survival rates.

Explore further: Late-stage sepsis suppresses immune system

More information: Bruno Francois et al, Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial, JCI Insight (2018). DOI: 10.1172/jci.insight.98960

Related Stories

Late-stage sepsis suppresses immune system

January 11, 2012
(Medical Xpress) -- Patients who die from sepsis are likely to have had suppressed immune systems that left them unable to fight infections, researchers at Washington University School of Medicine in St. Louis have shown.

Scientists find potential mechanism for deadly, sepsis-induced secondary infection

September 14, 2017
In mice, an infection-induced condition known as sepsis may increase the risk of life-threatening secondary infection by preventing recruitment of infection-fighting cells to the skin, according to new research published ...

Scientists discover new method to restore function of white blood cells in septic patients

December 1, 2016
New research findings published in the Journal of Leukocyte Biology, suggest that treating the white blood cells of sepsis patients with antibodies that block programmed cell death-1 (PD-1) and programmed cell death ligand ...

Immune system simulation shows need for multi-target treatments for sepsis

February 15, 2018
Using a computational model of the human immune system, scientists have shown that efforts to combat sepsis might be more effective if they targeted multiple steps in the molecular processes that drive the illness. This finding ...

HMGB1 may be linked to immunosuppression in patients who survive septic shock

June 1, 2017
A new study published online in the Journal of Leukocyte Biology suggests a new approach to treating patients with sepsis, one of the most frequent causes of morbidity and mortality in intensive care units (ICUs). Specifically, ...

Dormant viruses re-emerge in patients with lingering sepsis, signaling immune suppression

June 11, 2014
A provocative study links prolonged episodes of sepsis—a life-threatening infection and leading cause of death in hospitals—to the reactivation of otherwise dormant viruses in the body.

Recommended for you

Obesity and health problems: New research on a safeguard mechanism

March 16, 2018
Obesity and its negative impacts on health - including metabolic syndrome, type-2 diabetes mellitus and cardiovascular complications - are a global pandemic (Taubes, 2009). The worldwide incidence of obesity has more than ...

Immune system 'double agent' could be new ally in cancer fight

March 16, 2018
St. Jude Children's Research Hospital scientists have discovered that an enzyme called TAK1 functions like a "double agent" in the innate immune response, serving as an unexpected regulator of inflammation and cell death. ...

Artificial sweetener Splenda could intensify symptoms in those with Crohn's disease

March 15, 2018
In a study that has implications for humans with inflammatory diseases, researchers from Case Western Reserve University School of Medicine and colleagues have found that, given over a six-week period, the artificial sweetener ...

Researchers identify common biological features of different types of asthma

March 14, 2018
A team of researchers from the NIHR Leicester Biomedical Research Centre - a partnership between Leicester's Hospitals, the University of Leicester and Loughborough University - has identified biological variations in lung ...

Scientists discover treatment target for sepsis

March 14, 2018
In a study published in Nature Communications, Northwestern Medicine scientists demonstrated the key role a molecule called oxPAPC plays in regulating the inflammatory response—findings which could inform the development ...

Researcher creates 'Instagram' of immune system, blending science, technology

March 10, 2018
Being on the cutting edge of science and technology excites Hollings Cancer Center (HCC) researcher Carsten Krieg, Ph.D. Each day, he walks into his lab that houses a mass cytometry machine aptly labeled Helios. Krieg explains ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.